Evidence map›Paper›PMID 41137052›Full record

ArticleJournal of cardiothoracic surgery2025

RBM15 is a novel prognostic biomarker and correlates with immune cell infiltration in lung adenocarcinoma.

Mingsheng Ma, Wei Wang, Li Li, Xiaoyan Wang, Qiubo Huang, Chen Zhou, Lianhua Ye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mingsheng Ma *Department of Thoracic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650000, China.
Wei Wang *Department of Thoracic Surgery, Taihe Hospital (Hubei University of Medicine), 442000, shiyan, China.
Li LiDepartment of Biotherapy Chemotherapy Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650000, yunnan, China.
Xiaoyan WangDepartment of Obstetrics, The Sixth Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.
Qiubo HuangDepartment of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, No.519 Kunzhou Road, Xishan District, Kunming City, 650000, Yunnan Province, China.
Chen ZhouDepartment of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, No.519 Kunzhou Road, Xishan District, Kunming City, 650000, Yunnan Province, China.
Lianhua YeDepartment of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, No.519 Kunzhou Road, Xishan District, Kunming City, 650000, Yunnan Province, China. lhye1204@aliyun.com.

Funding

Graduate Innovation Foundation of Kunming Medical University No.2022B14National Natural Science Foundation of China No. 8160325Natural Science Foundation of Hubei Province No. 2023AFB325Scientific Research Fund Project of Education Department of Yunnan Province No.2023Y0695Scientific Research Fund Project of Education Department of Yunnan Province No.2023Y0697Yunnan Fundamental Research Projects NO. 202301AY070001-110
6 · The paper itself

Abstract

BACKGROUND AND

aimsThis study aimed to evaluate RBM15 gene expression and the potential effects as a biomarker in LUAD progression. MATERIALS AND

methodsThe RNA sequencing (RNA-seq) data and clinical data of patients with LUAD were acquired from The Cancer Genome Atlas (TCGA) databases. Kaplan-Meier (K-M) curves were generated to investigate the relationship between RBM15 and the prognosis of patients with LUAD. Gene Ontology (GO) and Reactome enrichment analyses were performed using the "cluster Profiler" R package. Finally, the Tumor Immune Estimation Resource (TIMER)database and CIBERSORT algorithm were used to assess the correlations between RBM15 expression and immune infiltration in LUAD.

resultsRBM15 was upregulated in tumor tissue, and it was regarded as an independent prognostic factor in LUAD. The genes co-expressed with RBM15 were closely related to cell cycle checkpoints and M phase signaling pathways. Furthermore, there was a significant correlation between RBM15 gene expression and immune infiltration in LUAD.

conclusionOur data suggested that RBM15 is critical in LUAD progression, is associated with tumor immune infiltration and served as a valuable potential diagnostic biomarker in patients.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorLung NeoplasmsRNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, TumorRNA-Binding ProteinsLung adenocarcinomaLymphocytes introductionPrognosisRBM15Tumor infiltration

Identifiers

PMID41137052
PMCPMC12553164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.